文献速递妇科

2025版ESGO/ESTRO/ESP术后风险分层在子宫内膜癌中的验证:与2020版分子分型的同队列比较

Validation of the 2025 ESGO/ESTRO/ESP postoperative risk stratification system in endometrial cancer: A same-cohort comparison with the 2020 molecular classification.
PubMed 文献 · Gynecol Oncol · 2026-07-14

该研究回顾性纳入295例子宫内膜癌手术患者,在同一队列中比较2020与2025版ESGO/ESTRO/ESP风险分层对无复发生存(RFS)的预后表现。2025版主要在中间风险谱内重新分配患者,模型层面预后表现优于2020版,且ER/分级整合的NSMP亚分类支持更新框架的生物学合理性。

要点

  • 2025版风险分层在中间风险谱内重新分配患者,该组30例无复发。
  • 2025版复发预测的调整Harrell一致性指数高于2020版(0.868 vs 0.855)。
  • NSMP肿瘤中高级别或ER阴性者5年RFS低于低级别ER阳性者(48.7% vs 93.5%)。

核心结论

  • 2025版ESGO/ESTRO/ESP分类在模型层面预后表现更优,并在中间风险谱内实现有临床意义的患者重新分配。
  • ER/分级整合的NSMP亚分类支持更新框架的生物学合理性。

研究设计与样本

  • 回顾性纳入2010至2021年在一家三级中心接受初次手术的295例子宫内膜癌患者。
  • 分别按2020版和2025版ESGO/ESTRO/ESP系统分配风险组。
  • 在可同时按两系统分类的277例患者中头对头评估预后表现,主要终点为无复发生存(RFS)。

主要发现

  • 2025版主要在中间风险谱内重新分配患者,分配至2025版中间风险组的30例患者无复发。
  • 头对头分析中,2025版复发预测的调整Harrell一致性指数为0.868(95%CI 0.826-0.909),2020版为0.855(95%CI 0.810-0.896)。
  • 2025版调整Akaike信息准则低于2020版(401.3 vs 416.9)。
  • 158例NSMP肿瘤中,高级别或ER阴性者5年RFS为48.7%,低于低级别ER阳性者的93.5%。
  • NSMP肿瘤中高级别或ER阴性经调整后仍与复发相关(调整风险比5.53,95%CI 1.79-17.11)。

临床怎么用

  • 在术后风险评估中可采用2025版ESGO/ESTRO/ESP分层,其在复发预测的模型层面表现优于2020版。
  • 对NSMP亚型应结合ER状态与肿瘤分级进一步细分,高级别或ER阴性者复发风险更高。

局限性

  • 回顾性单中心设计,样本来自2010至2021年一家三级中心。
  • 头对头预后分析仅纳入可同时按两系统分类的277例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative risk stratification of endometrial cancer has increasingly integrated clinicopathological and molecular features. The clinical value of the 2025 ESGO/ESTRO/ESP update and estrogen receptor (ER)/grade-integrated nonspecific molecular profile (NSMP) sub-classification requires independent real-world evaluation. METHODS: We retrospectively included 295 patients with endometrial carcinoma who underwent primary surgery at a tertiary center between 2010 and 2021. Risk groups were assigned according to both the 2020 and 2025 ESGO/ESTRO/ESP systems. The head-to-head prognostic performance was evaluated in 277 patients classifiable under both systems. The primary endpoint was recurrence-free survival (RFS). RESULTS: The 2025 system redistributed patients mainly within the intermediate-risk spectrum. No recurrences occurred in the 30 patients assigned to the 2025 intermediate-risk group. In head-to-head analysis, the 2025 system showed a higher adjusted Harrell's concordance index (0.868, 95% CI 0.826-0.909 vs 0.855, 95% CI 0.810-0.896) and lower adjusted Akaike information criterion (401.3 vs 416.9) than the 2020 system for recurrence prediction. Among the 158 NSMP tumors, high-grade or ER-negative tumors were associated with worse 5-year recurrence-free survival than low-grade ER-positive tumors (48.7% vs. 93.5%) and remained associated with recurrence after adjustment (adjusted hazard ratio 5.53, 95% confidence interval 1.79-17.11). CONCLUSIONS: The 2025 ESGO/ESTRO/ESP classification demonstrated better model-level prognostic performance and clinically meaningful patient redistribution, particularly within the intermediate-risk spectrum. The ER/grade-integrated NSMP subclassification supports the biological rationale of the updated framework.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jeong S, Kim S, Ouh YT, et al. Validation of the 2025 ESGO/ESTRO/ESP postoperative risk stratification system in endometrial cancer: A same-cohort comparison with the 2020 molecular classification. Gynecol Oncol. 2026. PMID: 42447656. doi:10.1016/j.ygyno.2026.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。